AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-13 (canceled)

Claim 14 (currently amended): A method of ~~preventing or controlling~~ inhibiting TGFβ-induced cataract or after-cataract formation in the eye of a mammalian subject in need of such ~~prevention or control~~ inhibition, which comprises the step of administering to the subject an effective amount of one or more inhibitors of TGFβ.

Claim 15 (previously presented): The method according to claim 14 wherein the one or more inhibitors of TGFβ are selected from proteins, gycloproteins and proteoglycans.

Claim 16 (previously presented): The method according to claim 15 wherein the protein inhibitors of TGFβ are selected from antibodies and peptide growth factors.

Claim 17 (previously presented): The method according to claim 15 wherein the glycoprotein inhibitors of TGFβ are selected from α_2-macroglobulin, laminin and collagen.

Claim 18 (previously presented): The method according to claim 15 wherein the proteoglycan inhibitors of TGFβ are selected from decorin, heparan sulfate proteoglycans and biglycan.

Claim 19 (previously presented): An ophthalmological formulation comprising one or more inhibitors of TGFβ in an ophthalmologically acceptable carrier but excluding conventional pharmaceutically acceptable carriers.

Claim 20 (previously presented): The ophthalmological formulation according to claim 19 wherein the one or more inhibitors of TGFβ are selected from proteins, glycoproteins and proteoglycans.

Claim 21 (previously presented): The ophthalmological formulation according to claim 20 wherein the protein inhibitors of TGFβ are selected from antibodies and peptide growth factors.

Claim 22 (previously presented): The ophthalmological formulation according to claim 20 wherein the glycoprotein inhibitors of TGFβ are selected from α_2-macroglobulin, laminin and collagen.

Claim 23 (previously presented): The ophthalmological formulation according to claim 20 wherein the proteoglycan inhibitors of TGFβ are selected from decorin, heparan sulfate proteoglycans and biglycan.

Claim 24 (currently amended): A method of ~~preventing or controlling~~ inhibiting after-cataract formation in the eye of a mammalian subject following lens implant surgery, which comprises the step of implanting in the eye of the subject a lens coated with one or more TGFβ inhibitors.

Claim 25 (previously presented): The method according to claim 24 wherein the one or more inhibitors of TGFβ are selected from proteins, glycoproteins and proteoglycans.

Claim 26 (previously presented): The method according to claim 25 wherein the protein inhibitors of TGFβ are selected from antibodies and peptide growth factors.

Claim 27 (previously presented): The method according to claim 25 wherein the glycoprotein inhibitors of TGFβ are selected from α_2-macroglobulin, laminin and collagen.

Claim 28 (previously presented): The method according to claim 25 wherein the proteoglycan inhibitors of TGFβ are selected from decorin, heparan sulfate proteoglycans and biglycan.

Claim 29 (withdrawn): A lens implant comprising a coating, the coating including one or more TGFβ inhibitors.

Claim 30 (withdrawn): The lens implant according to claim 29 coated with one or more TGFβ inhibitors selected from proteins, glycoproteins and proteoglycans.

Claim 31 (withdrawn): The lens implant according to claim 30 wherein the protein inhibitors of TGFβ are selected from antibodies and peptide growth factors.

Claim 32 (withdrawn): The lens implant according to claim 30 wherein the glycoprotein inhibitors of TGFβ are selected from α_2-macroglobulin, laminin and collagen.

Claim 33 (withdrawn): The lens implant according to claim 30 wherein the proteoglycan inhibitors of TGFβ are selected from decorin, heparan sulfate proteoglycans and biglycan.

Claims 34-38 (canceled)